Franklin Biotechnology Discovery Fund I(acc)EUR-H1Register to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 34.5 | -22.6 | -9.5 | 12.8 | 2.3 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 02/05/2024 | EUR 24.64 | |
Day Change | 0.76% | |
Morningstar Category™ | Other Equity | |
ISIN | LU0889565759 | |
Fund Size (Mil) 31/03/2024 | USD 1785.11 | |
Share Class Size (Mil) 02/05/2024 | EUR 7.72 | |
Max Initial Charge | - | |
Ongoing Charge 08/02/2023 | 0.96% |
Investment Objective: Franklin Biotechnology Discovery Fund I(acc)EUR-H1 |
The Fund’s investment objective is capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Wendy Lam 01/09/2018 | ||
Click here to see others | ||
Inception Date 26/02/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Franklin Biotechnology Discovery Fund I(acc)EUR-H1 | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 6.85 |
Regeneron Pharmaceuticals Inc | Healthcare | 6.43 |
Vertex Pharmaceuticals Inc | Healthcare | 5.34 |
Ascendis Pharma A/S ADR | Healthcare | 4.22 |
Gilead Sciences Inc | Healthcare | 3.07 |
Increase Decrease New since last portfolio | ||
Franklin Biotechnology Discovery Fund I(acc)EUR-H1 |